COVID-19 Vaccinology: Development, Use and Effect on Public Health
IKEEP. Shabir A. Madhi N. 01/21/21; 314023
Neelika Malavige & Shabir A. Madhi
Neelika Malavige & Shabir A. Madhi
Contributions Biography
About this activity
Abstract
This webinar will provide important updates in the currently approved COVID-19 vaccines and an overview of ongoing Phase 3 trials. Attention will be paid to the vaccination of special groups such as immunocompromised individuals, children and pregnant women. Since its appearance in December 2019, SARS-CoV-2 has developed a substantial number of mutations, especially in the S-protein. The implications of such mutations on vaccine response will be addressed. We shall also discuss the elements required to achieve herd immunity and answer your questions about COVID-19 vaccination.

Evaluation Form: After the session click here to complete a 2 minute survey to share your feedback
Where are we with delivering safe, effacious COVID-19 vaccines globally? What are the challenges and opportunities? This webinar will provide important updates in the currently approved COVID-19 vaccines and an overview of ongoing Phase 3 trials. Attention will be paid to the vaccination of special groups such as immunocompromised individuals, children, and pregnant women. We shall also discuss the elements required to achieve herd immunity.
Where are we with delivering safe, effacious COVID-19 vaccines globally? What are the challenges and opportunities? This webinar will provide important updates in the currently approved COVID-19 vaccines and an overview of ongoing Phase 3 trials. Attention will be paid to the vaccination of special groups such as immunocompromised individuals, children, and pregnant women. We shall also discuss the elements required to achieve herd immunity.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies